Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $10,814.10 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 1,695 shares of the stock in a transaction on Monday, April 29th. The stock was sold at an average price of $6.38, for a total transaction of $10,814.10. Following the transaction, the chief financial officer now directly owns 339,803 shares in the company, valued at $2,167,943.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Thomas Catinazzo also recently made the following trade(s):

• On Wednesday, March 27th, Thomas Catinazzo sold 348 shares of Relay Therapeutics stock. The stock was sold at an average price of $7.70, for a total value of $2,679.60.

Relay Therapeutics Stock Performance

RLAY traded up $0.22 during mid-day trading on Monday, reaching $6.59. 979,096 shares of the stock were exchanged, compared to its average volume of 1,146,407. Relay Therapeutics, Inc. has a 1 year low of $5.70 and a 1 year high of $13.32. The stock has a market capitalization of $872.12 million, a PE ratio of -2.35 and a beta of 1.63. The company has a 50 day moving average price of $8.15 and a two-hundred day moving average price of $8.81.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.09. Relay Therapeutics had a negative net margin of 1,263.49% and a negative return on equity of 42.43%. During the same quarter in the previous year, the firm earned ($0.56) EPS. Sell-side analysts expect that Relay Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on RLAY shares. Leerink Partnrs reaffirmed an "outperform" rating on shares of Relay Therapeutics in a research note on Thursday, February 22nd. Stifel Nicolaus raised their price target on shares of Relay Therapeutics from $25.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, February 22nd. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $26.00.

Institutional Trading of Relay Therapeutics

Hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new position in Relay Therapeutics in the third quarter valued at about $323,000. Intellectus Partners LLC increased its position in Relay Therapeutics by 4.1% in the third quarter. Intellectus Partners LLC now owns 50,560 shares of the company's stock worth $425,000 after buying an additional 2,000 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Relay Therapeutics by 37.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,165 shares of the company's stock valued at $161,000 after buying an additional 5,222 shares during the period. TD Asset Management Inc raised its stake in shares of Relay Therapeutics by 88.8% in the third quarter. TD Asset Management Inc now owns 497,490 shares of the company's stock valued at $4,184,000 after buying an additional 233,983 shares during the period. Finally, M&T Bank Corp lifted its position in shares of Relay Therapeutics by 46.7% during the 3rd quarter. M&T Bank Corp now owns 46,013 shares of the company's stock valued at $387,000 after buying an additional 14,645 shares during the last quarter. 96.98% of the stock is currently owned by institutional investors.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.